Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CAR-γδT Cell Injection for Relapsed AML Post-Transplantation
NCT04796441Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute myeloid leukemia (AML), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04796441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796441.